Published: August 2026
Medically reviewed by:
Gary Falcetano, PA-C, AE-C
The biggest challenge in first-line testing isn't whether to test. It's knowing what to test.
For many primary care physicians, patients present similar symptoms, yet the underlying allergen triggers may be very different. Clinical history remains the foundation of allergy assessment, but it does not always identify which allergens should be prioritized for first-line testing. Selecting clinically relevant allergens early can help support more confident diagnosis and patient management.1,7,8
Selected, clinically relevant ImmunoCAP™ Specific IgE allergen profiles support a clinically guided approach to first-line testing by helping primary care physicians prioritize relevant allergens, simplify test ordering and provide quantitative specific IgE results that can help physicians interpret sensitization results with greater confidence and support informed clinical decision-making.
Why choosing the right allergens matters
Many patients are sensitized to more than one allergen (polysensitization), meaning clinicians often need to consider several potential allergen triggers rather than a single allergen when planning first-line allergy assessment.1-3 This highlights the importance of selecting clinically relevant allergens to support confident diagnosis.
Selecting too few allergens may miss clinically relevant sensitizations, while broad, indiscriminate testing may identify sensitizations that complicate interpretation without improving clinical decision-making.4,6
International guidance recommend a clinically guided approach based on the patient's clinical history, symptoms, and likely environmental exposures.1,5,6, This approach focuses on selecting clinically relevant allergens based on patient history rather than broad, indiscriminate testing. Quantitative ImmunoCAP™ Specific IgE results help physicians identify clinically relevant sensitizations more confidently and support first-line clinical decision-making.1,5
Selected, clinically relevant allergen profiles provide a practical way to answer that question by supporting a more systematic approach to first-line allergen selection.1,6,10
The question is no longer: "How many allergens should I test?" Instead, it becomes: "Which selected, clinically relevant allergens should I prioritize first?"
How clinically relevant ImmunoCAP Specific IgE allergen profiles* support first-line testing
Selected, clinically relevant ImmunoCAP Specific IgE allergen profiles provide a practical starting point for first-line testing.
They can be particularly valuable when:1,2,8
- Clinical history does not provide a clear understanding of allergic triggers.
- Symptoms are unclear, persistent, or overlapping.
- Multiple allergen triggers are suspected.
- Current treatment has not provided adequate symptom control.
- Multiple sensitizations are suspected.
Profiles should be developed locally to reflect regional allergens, clinical practice, and reimbursement. Physicians, together with laboratory specialists, continue to decide which allergens are most appropriate based on the patient's history, clinical judgement, and local guidance.
Confident first-line testing starts with choosing the right allergens
Choosing the right allergens at the start of the diagnostic journey helps physicians identify clinically relevant sensitizations earlier, support more informed patient management, and determine when referral to an allergy specialist may be appropriate.
By simplifying first-line allergen selection, clinically relevant ImmunoCAP Specific IgE allergen profiles help primary care physicians move from uncertainty to informed clinical decision-making with greater confidence. The ImmunoCAP allergy solutions define the standard for in vitro allergy diagnostics9, delivering clinically proven, reproducible results that enable confident allergy diagnosis and management, while supporting clinically guided first-line allergen selection.
Ultimately, the goal isn't to perform more testing. It's to perform the right testing. Selecting clinically relevant allergens from the start - not broad, indiscriminate testing - helps bring greater clarity to allergy assessment, supports more confident clinical decision-making and enables more informed patient management.1,4,6,10
Frequently asked questions
Clinically relevant ImmunoCAP Specific IgE allergen profiles combine individually available ImmunoCAP allergen tests into locally developed, clinically relevant profiles that support a clinically guided approach to first-line Specific IgE testing.
They can be particularly helpful when clinical history does not clearly identify which allergens to test; symptoms are persistent or overlapping, or multiple allergen triggers are suspected.
No. These profiles are designed to support and not replace clinical decision-making. Patient history, physician judgement, and local guidance should always determine the final allergen selection.
Contact your local laboratory to learn more about available clinically relevant allergen profiles.
* ImmunoCAP Specific IgE allergen profiles are laboratory-defined testing profiles consisting of individually available ImmunoCAP allergen tests selected to reflect local clinical needs.
